Diabetes Obes Metab 14(12):10881096 Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A et al (2013) Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes
The high-dose version is already approved in the EU in a vial formulation under the Wegovy HD brand name, and is another important line extension for Novo Nordisk as it tries to protect its weight-loss franchise from Lilly's rival injectable Zepbound/Mounjaro (tirzepatide)
Hormone replacement therapy (HRT) and contraception are commonly prescribed in primary care, and both are potentially affected by GLP-1 agonists
Participants receiving the highest dose lost significantly more weight compared to placebo groups, with benefits sustained as long as treatment continued
Reach Out
A vial left in a hot car for 6 hours suffers more damage than one left at room temperature for 24 hours